Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Understanding the potential of TIGIT targeting drugs in treating advanced or recurrent cancers, such as Gilead's domvanalimab for treating metastatic lung cancer.

Ticker(s): GILD

Who's the expert?

Professor of Medicine, Immunology and Dermatology
Published heavily on TIGIT targeting therapies
Co-leader of the Cancer Immunology and Immunotherapy Program and Co-leader of the Melanoma and Skin Cancer SPORE

Interview Goal

To better understand the potential of TIGIT-targeted drugs with an emphasis on the ongoing phase 2 ARC-7 trial studying domvanalimab as an anti-TIGIT approach to treat patients with metastatic lung cancer.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.